RCKT
ROCKET PHARMACEUTICALS, INC.
$2.75
+3.38%
$300.3M
No data for this timeframe.
Vol
Market Cap$300.3M
Cap SizeSmall Cap
Analyst ConsensusBuy (55%)
Inst. Holders50 funds
Inst. Value$238.9M
Inst. Activity15 buys / 5 sells
Insider Activity0B / 10S
Insider Net $-$300.4K
Reddit Sentiment77° Bullish
SEC Reports5
Recent Activity
Aug 5, 2026
earnings_calendar
RCKT Q2 2026 Earnings After Market Close — 2026-08-05
EPS est: $-0.40 | Rev est: $0.0B
Jun 12, 2026
SEC
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million i
8-K — Impact 5/10
May 26, 2026
SEC
CEO Gaurav Shah exercised 76,490 options at $1.69 and immediately sold 55,684 shares on the open market for ~$172K, a cl
CLUSTER — Impact 3/10
May 26, 2026
Insider
Militello John was granted 51,509 shares
See Remarks
May 26, 2026
Insider
Militello John disposed of 10,000 shares
See Remarks
May 21, 2026
Insider
Shah Gaurav acquired via exercise 76,490 shares
CEO @ $1.69 ($129.3K)
May 14, 2026
SEC
Rocket Pharmaceuticals CEO Gaurav Shah sold $10K worth of shares and another insider sold $68K, totaling $78K in open-ma
CLUSTER — Impact 3/10
Inst.
STATE STREET CORP — DOUBLED
4,485,989 shares ($16.1M)
Price Targets
$9.39
+241.3% upside
Strong Buy
Current $2.75
Low $3.00
Median $10.00
High $16.00
11 analysts
$3.00
$16.00
Analyst Ratings
4Strong Buy
7Buy
7Hold
2Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 30, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Sell → Sell |
| Feb 27, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.35 | $-0.54 — $1.15 | 160% YoY | 7 |
| Next Q | $-0.43 | $-0.51 — $-0.31 | 5% YoY | 5 |
| Current FY | $-0.82 ▲ +40.2% | $-1.98 — $-0.12 | 59% YoY | 8 |
| Next FY | $-1.13 ▲ +15.3% | $-1.88 — $-0.12 | -38% YoY | 7 |
Latest Reports
BULLISH
8-K
5/10
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million i
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
CEO Gaurav Shah exercised 76,490 options at $1.69 and immediately sold 55,684 shares on the open market for ~$172K, a cl
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RTW INVESTMENTS, LP | $63.3M | — |
| BlackRock, Inc. | $28.0M | — |
| CITIGROUP INC | $18.3M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $16.8M | — |
| STATE STREET CORP | $16.1M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Militello John | A | $0.00 |
| May 26, 2026 | Militello John | D | $0.00 |
| May 21, 2026 | Shah Gaurav | M | $129.3K |
| May 21, 2026 | Shah Gaurav | SELL | $171.8K |
| May 19, 2026 | Shah Gaurav | SELL | $7.3K |
Reddit Sentiment
77°
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $238.9M total value (66,726,695 shares) as of 2026-Q1. Top holders: RTW, BlackRock,, CITIGROUP. Net buying activity: 15 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 17,687,772 | $63.3M | 26.5% | — |
| 2 | BlackRock, Inc. | 7,834,795 | $28.0M | 11.7% | — |
| 3 | CITIGROUP INC | 5,107,708 | $18.3M | 7.7% | — |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,690,215 | $16.8M | 7.0% | — |
| 5 | STATE STREET CORP | 4,485,989 | $16.1M | 6.7% | DOUBLED +163.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3,775,736 | $13.5M | 5.7% | — |
| 7 | Nuveen, LLC | 3,128,753 | $11.2M | 4.7% | DOUBLED +1880.1% |
| 8 | MARSHALL WACE, LLP | 3,038,715 | $10.9M | 4.6% | DOUBLED +11433.4% |
| 9 | D. E. Shaw & Co., Inc. | 2,169,625 | $7.8M | 3.3% | DOUBLED +120.6% |
| 10 | MORGAN STANLEY | 2,020,108 | $7.2M | 3.0% | TRIM -48.7% |
| 11 | GOLDMAN SACHS GROUP INC | 1,721,116 | $6.2M | 2.6% | — |
| 12 | TWO SIGMA INVESTMENTS, LP | 1,097,623 | $3.9M | 1.6% | ADD +32.4% |
| 13 | FEDERATED HERMES, INC. | 1,023,747 | $3.7M | 1.5% | ADD +40.4% |
| 14 | Point72 Asset Management, L.P. | 1,012,126 | $3.6M | 1.5% | ADD +99.3% |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 724,392 | $2.6M | 1.1% | — |
| 16 | Woodline Partners LP | 641,222 | $2.3M | 1.0% | — |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 637,174 | $2.3M | 1.0% | ADD +51.3% |
| 18 | BANK OF AMERICA CORP /DE/ | 630,125 | $2.3M | 0.9% | — |
| 19 | VANGUARD FIDUCIARY TRUST CO | 590,750 | $2.1M | 0.9% | — |
| 20 | DEUTSCHE BANK AG\ | 482,079 | $1.7M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 1,700,631 | 4,485,989 | +163.8% | $16.1M | 2026-Q1 |
| Nuveen, LLC | DOUBLED | 158,012 | 3,128,753 | +1880.1% | $11.2M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 26,347 | 3,038,715 | +11433.4% | $10.9M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 3,941,377 | 2,020,108 | -48.7% | $7.2M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 507,909 | 1,012,126 | +99.3% | $3.6M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 421,174 | 637,174 | +51.3% | $2.3M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 400,706 | 259,007 | -35.4% | $927.2K | 2026-Q1 |
| Mariner, LLC | DOUBLED | 12,634 | 190,111 | +1404.8% | $680.5K | 2026-Q1 |
| CWM, LLC | DOUBLED | 32,480 | 174,263 | +436.5% | $623.9K | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 32,515 | 99,026 | +204.6% | $354.5K | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 178,926 | 95,180 | -46.8% | $340.7K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 18,230 | 80,868 | +343.6% | $287.1K | 2026-Q1 |
| Cerity Partners LLC | DOUBLED | 22,792 | 78,974 | +246.5% | $282.7K | 2026-Q1 |
| Marex Group plc | ADD | 57,500 | 72,500 | +26.1% | $259.6K | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 102,538 | 68,046 | -33.6% | $243.6K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 95,100 | 61,300 | -35.5% | $219.5K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 9,204 | 57,382 | +523.4% | $205.4K | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 10,229 | 54,603 | +433.8% | $195.5K | 2026-Q1 |
| MetLife Investment Management, LLC | ADD | 33,480 | 46,551 | +39.0% | $166.7K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 2,988 | 8,700 | +191.2% | $31.1K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 1,609,682 | 2,131,929 | +32.4% | $7.5M | 2025-Q4 |
| FEDERATED HERMES, INC. | ADD | 627,567 | 881,249 | +40.4% | $3.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 137,177 | 421,174 | +207.0% | $1.5M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 1,313,737 | 400,706 | -69.5% | $1.4M | 2025-Q4 |
| FMR LLC | ADD | 311,701 | 395,275 | +26.8% | $1.4M | 2025-Q4 |
6 unique insiders with 25 transactions. Net insider value: -$300.4K ($0.00 bought, $300.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Militello John | See Remarks | AWARD | 51,509 | — | — |
| May 26, 2026 | Militello John | See Remarks | D | 10,000 | — | — |
| May 21, 2026 | Shah Gaurav | CEO | EXERCISE | 76,490 | $1.69 | $129.3K |
| May 21, 2026 | Shah Gaurav | CEO | SELL | 55,684 | $3.09 | $171.8K |
| May 19, 2026 | Shah Gaurav | CEO | SELL | 2,409 | $3.01 | $7.3K |
| May 19, 2026 | Wilson Martin | General Counsel | SELL | 662 | $3.01 | $2.0K |
| May 19, 2026 | Militello John | See Remarks | SELL | 384 | $3.01 | $1.2K |
| May 13, 2026 | Shah Gaurav | CEO | SELL | 2,728 | $3.61 | $9.8K |
| May 13, 2026 | Wilson Martin | General Counsel | SELL | 3,361 | $3.61 | $12.1K |
| May 7, 2026 | Chaudhuri Sarbani | See Remarks | SELL | 17,650 | $3.84 | $67.7K |
| Feb 18, 2026 | Shah Gaurav | CEO | SELL | 5,990 | $3.34 | $20.0K |
| Feb 18, 2026 | Militello John | See Remarks | SELL | 1,157 | $3.34 | $3.9K |
| Feb 18, 2026 | Wilson Martin | General Counsel | SELL | 1,376 | $3.34 | $4.6K |
| Feb 11, 2026 | Wilson Martin | General Counsel | AWARD | 311,813 | — | — |
| Feb 11, 2026 | Wilson Martin | General Counsel | AWARD | 468,187 | — | — |
| Feb 11, 2026 | Militello John | See Remarks | AWARD | 29,982 | — | — |
| Feb 11, 2026 | Militello John | See Remarks | AWARD | 45,018 | — | — |
| Feb 11, 2026 | Rizvi Syed Ali-aamir | Chief Medical Officer | AWARD | 61,963 | — | — |
| Feb 11, 2026 | Rizvi Syed Ali-aamir | Chief Medical Officer | AWARD | 93,037 | — | — |
| Feb 11, 2026 | Stevens Christopher James | Chief Operating Officer | AWARD | 61,963 | — | — |
| Feb 11, 2026 | Stevens Christopher James | Chief Operating Officer | AWARD | 93,037 | — | — |
| Feb 11, 2026 | Chaudhuri Sarbani | See Remarks | AWARD | 125,924 | — | — |
| Feb 11, 2026 | Chaudhuri Sarbani | See Remarks | AWARD | 189,076 | — | — |
| Feb 11, 2026 | Shah Gaurav | CEO | AWARD | 286,028 | — | — |
| Feb 11, 2026 | Shah Gaurav | CEO | AWARD | 870,648 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
BULLISH
8-K
5/10
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
CEO Gaurav Shah exercised 76,490 options at $1.69 and immediately sold 55,684 shares on the open mar
May 26, 2026
NEUTRAL
CLUSTER
3/10
Rocket Pharmaceuticals CEO Gaurav Shah sold $10K worth of shares and another insider sold $68K, tota
May 14, 2026
NEUTRAL
EFFECT
4/10
Rocket Pharmaceuticals, Inc. has an effective shelf registration (Form S-3) as of March 10, 2026, al
Mar 11, 2026
BEARISH
S-3
7/10
Rocket Pharmaceuticals has filed a shelf registration (S-3) for up to $400 million in securities, in
Mar 2, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (55% buy). Based on 20 analysts: 4 strong buy, 7 buy, 7 hold, 2 sell, 0 strong sell.
Analyst Price Targets
$9.39 mean target
+241.3% upside
Strong Buy (2.46)
$3.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $2.75 |
| Target Low | $3.00 |
| Target Mean | $9.39 |
| Target Median | $10.00 |
| Target High | $16.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (2.46) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.35 | $-0.54 | $1.15 | 160.1% | — | 2↑ 1↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.43 | $-0.51 | $-0.31 | 5.0% | — | 1↑ 1↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-0.82 | $-1.98 | $-0.12 | 58.7% | +40.2% | 2↑ 1↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-1.13 | $-1.88 | $-0.12 | -38.0% | +15.3% | 1↑ 2↓ | $0.0B | 15.3% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.354 | |
| 7d ago | $0.127 | +0.227 |
| 30d ago | $0.000 | +0.354 |
| 60d ago | $0.000 | +0.354 |
| 90d ago | $-0.123 | +0.478 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 30, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Sell | Sell |
| Feb 27, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| May 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Apr 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Mar 1, 2026 | 5 | 7 | 7 | 2 | 0 | 57% | |
| Feb 1, 2026 | 5 | 7 | 7 | 2 | 0 | 57% | |
| Jan 1, 2026 | 5 | 7 | 7 | 2 | 0 | 57% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
77°
Bullish
Bearish
Neutral
Bullish
24 mentions
17 bullish
2 bearish
24 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 14, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 14, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 2, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 28, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Rocket Pharmaceuticals 1-2 month outlook? (RCKT)
▲ 1
💬 0
⚡ 0.5
ALGUIEN MAS CON RCKT?
▲ 1
💬 1
⚡ 0.5
Whe The Market Might Rocket Over RCKT
▲ 1
💬 0
⚡ 0.5
Rocket pharmaceuticals gets FDA approval (RCKT)
▲ 1
💬 0
⚡ 0.5
Rocket pharmaceuticals gets FDA approval (RCKT)
▲ 1
💬 1
⚡ 0.5
Rocket Pharmaceuticals gets FDA approval (RCKT)
▲ 1
💬 0
⚡ 0.5
(RCKT) has just secured FDA approval and $200 million in funding. Hurry. A minimum of 260%–300% is easy.
▲ 1
💬 0
⚡ 0.5
Rocket Pharma (RCKT) FDA Approval SHORT SQUUEEEEEEZE!
▲ 1
💬 0
⚡ 0.5
Is anyone else buying RCKT ?
▲ 1
💬 1
⚡ 0.5
RCKT Setup Going Into PDUFA What’s the Play
▲ 1
💬 1
⚡ 0.5
DD: RCKT short squeeze imminent due to FDA apprval?
▲ 1
💬 1
⚡ 0.5
Will shorter get squeezed for RCKT?
▲ 1
💬 0
⚡ 0.5
$RCKT: Why I think March 28 is a re-rating event, not just a sell-the-news biotech catalyst
▲ 1
💬 1
⚡ 0.5
RCKT buy sell or hold?
▲ 1
💬 0
⚡ 0.1
RCKT FLYING UP 16% TODAY
▲ 1
💬 1
⚡ 0.0
Aug 5, 2026
earnings_calendar
RCKT Q2 2026 Earnings After Market Close — 2026-08-05
EPS est: $-0.40 | Rev est: $0.0B
Jun 5, 2026
short_volume
Short Volume: RCKT — 60.0% short (0.8M / 1.3M)
Short: 803,539 | Exempt: 2,644 | TRF Vol: 1,339,664 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: RCKT — 56.4% short (1.1M / 2.0M)
Short: 1,128,043 | Exempt: 14,537 | TRF Vol: 2,000,317 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: RCKT — 59.4% short (0.5M / 0.9M)
Short: 546,548 | Exempt: 0 | TRF Vol: 920,529 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: RCKT — 55.5% short (0.7M / 1.2M)
Short: 653,781 | Exempt: 6,951 | TRF Vol: 1,178,895 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: RCKT — 57.8% short (0.6M / 1.1M)
Short: 619,375 | Exempt: 4,343 | TRF Vol: 1,070,675 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: RCKT — 65.6% short (0.9M / 1.4M)
Short: 896,989 | Exempt: 174 | TRF Vol: 1,367,235 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: RCKT — 56.9% short (0.9M / 1.7M)
Short: 944,591 | Exempt: 6,397 | TRF Vol: 1,658,908 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: RCKT — 65.3% short (0.6M / 0.9M)
Short: 585,422 | Exempt: 380 | TRF Vol: 895,888 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: RCKT — 60.0% short (0.7M / 1.2M)
Short: 701,985 | Exempt: 66 | TRF Vol: 1,169,398 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: RCKT — 63.1% short (0.4M / 0.7M)
Short: 413,293 | Exempt: 63 | TRF Vol: 654,645 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: RCKT — 58.7% short (0.5M / 0.8M)
Short: 476,044 | Exempt: 20 | TRF Vol: 811,290 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
RCKT Q1 2026 Earnings After Market Close — 2026-05-11
May 8, 2026
short_volume
Short Volume: RCKT — 64.3% short (0.8M / 1.2M)
Short: 767,722 | Exempt: 1,111 | TRF Vol: 1,193,180 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: RCKT — 59.6% short (0.5M / 0.9M)
Short: 518,493 | Exempt: 509 | TRF Vol: 869,844 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)